Back to Search
Start Over
Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer.
- Source :
-
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Feb; Vol. 191, pp. 110059. Date of Electronic Publication: 2023 Dec 20. - Publication Year :
- 2024
-
Abstract
- Background and Purpose: Due to the high intrinsic radioresistance of pancreatic ductal adenocarcinoma (PDAC), radiotherapy (RT) is only beneficial in 30% of patients. Therefore, this study aimed to identify targets to improve the efficacy of RT in PDAC.<br />Materials and Methods: Alamar Blue proliferation and colony formation assay (CFA) were used to determine the radioresponse of a cohort of 38 murine PDAC cell lines. A gene set enrichment analysis was performed to reveal differentially expressed pathways. CFA, cell cycle distribution, γH2AX FACS analysis, and Caspase 3/7 SYTOX assay were used to examine the effect of a combination treatment using KIRA8 as an IRE1α-inhibitor and Ceapin-A7 as an inhibitor against ATF6.<br />Results: The unfolded protein response (UPR) was identified as a pathway highly expressed in radioresistant cell lines. Using the IRE1α-inhibitor KIRA8 or the ATF6-inhibitor Ceapin-A7 in combination with radiation, a radiosensitizing effect was observed in radioresistant cell lines, but no substantial alteration of the radioresponse in radiosensitive cell lines. Mechanistically, increased apoptosis by KIRA8 in combination with radiation and a cell cycle arrest in the G1 phase after ATF6 inhibition and radiation have been observed in radioresistant cell lines.<br />Conclusion: So, our data show evidence that the UPR is involved in radioresistance of PDAC. Increased apoptosis and a G1 cell cycle arrest seem to be responsible for the radiosensitizing effect of UPR inhibition. These findings are supportive for developing novel combination treatment concepts in PDAC to overcome radioresistance.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023. Published by Elsevier B.V.)
- Subjects :
- Humans
Animals
Mice
Endoribonucleases genetics
Endoribonucleases metabolism
Endoribonucleases pharmacology
Protein Serine-Threonine Kinases genetics
Protein Serine-Threonine Kinases metabolism
Protein Serine-Threonine Kinases pharmacology
Cell Line, Tumor
Unfolded Protein Response
Apoptosis
Cell Proliferation
Pancreatic Neoplasms radiotherapy
Carcinoma, Pancreatic Ductal radiotherapy
Carcinoma, Pancreatic Ductal drug therapy
Carcinoma, Pancreatic Ductal genetics
Radiation-Sensitizing Agents pharmacology
Radiation-Sensitizing Agents therapeutic use
Benzenesulfonamides
Naphthalenes
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0887
- Volume :
- 191
- Database :
- MEDLINE
- Journal :
- Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38135186
- Full Text :
- https://doi.org/10.1016/j.radonc.2023.110059